Predictions and estimations of colorectal cancer mortality, prevalence and incidence in Aragon, Spain, for the period 1998-2022.

OBJECTIVE: estimate colorectal cancer incidence and prevalence in, based on mortality and survival data from the period 1998-2007, and provide projections of incidence, prevalence and mortality until the year 2022. METHODS: general and colorectal cancer mortality rates were obtained from the National Statistics Institute and survival data was obtained from the EUROCARE study. Estimations were carried out through the program MIAMOD. The joinpoint program was used to quantify the annual change expected in the projections. RESULTS: in men, an increase in prevalence is expected, from 237.2 (Crude Rate - CR = 303.5) to 237.7 (CR = 412.7) per 100.000 inhabitants/year in 2022. Incidence rates would increase from 48.2 (CR = 61.6) in 2007 to 55.2 (CR = 83.1), and mortality would increase from 22.7 (CR = 29.4) to 26.0 (CR = 39.6) when comparing 2007 and women, a reduction in prevalence is expected from 181.5 (CR = 268.3) to 167.9 (CR = 286.2) cases per 100,000 inhabitants/year. Incidence would change from 25.0 (CR = 38.0) in 2007 to 22.7 (CR = 39.2), and for mortality there is also an expected decrease, from 11.3 (CR =18.0) to 10.3 (CR = 18.5). CONCLUSION: the projections indicate that colorectal cancer in follows an increasing trend in incidence, mortality and prevalencein men, in opposition to corresponding decreasing trends in women.These projections must be considered in order to plan more effective prevention and treatment measures.

Laryngeal cancer survival in Zaragoza (Spain): a population-based study

OBJECTIVE: This article aims to study larynx cancer survival from the Population-Based Cancer Registry of Zaragoza, Spain, for the period 1978-2002. METHODS: The survival rates were calculated using the Kaplan-Meier method. The automated calculation of the Catalan Institute of Oncology was utilised to obtain the relative survival. RESULTS: The observed survival rate was 84.6% in the first year and 60.9% in the fifth year. The one-year relative survival in both genders was 86.8% (CI 95%: 85.3-88.4) and 70.1% (CI 95%: 67.8-72.4) after five years. Glottic cancer presented a better survival rate than supraglottic and subglottic cancers, and a better survival rate was also observed in younger ages. There were no statistical differences when comparing survival rates by gender and between the periods 1978-1986, 1987-1994 and 1995-2002. CONCLUSIONS: The data suggest there were no significant changes in laryngeal cancer survival in the province of Zaragoza in the period 1978-2002 and that the tumours located in the glottis presented a better prognosis (AU)